CooperSurgical terminates InnerDyne agreement:
This article was originally published in Clinica
CooperSurgical has terminated an agreement to fund the development and clinical trials of InnerDyne's thermal endometrial ablation technology for gynaecological applications. The termination was due to delays in product development which prevented CooperSurgical from fully evaluating the system's clinical safety and efficacy, says the company. CooperSurgical also claims competing endometrial ablation technologies are more likely to gain market approval before InnerDyne's products. Nicholas Pichotta, CooperSurgical's president, says his company is currently pursuing other opportunities to acquire or licence additional products within the surgical gynaecology strategy.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.